Shots:

• The two P-III EMPERIAL-preserved & -reduced studies involve assessing the effect of 12wks. treatment of Jardiance (qd- 10mg) vs PBO in 315 & 312 patients with CHF along with HFpEF & HFrEF respectively
• The two P-III EMPERIAL-reduced & EMPERIAL-preserved studies demonstrated no change in baseline to 12wks. in exercise ability- as measured by the six-minute walk test- no new safety is identified
• Jardiance (empagliflozin- qd- 20mg) is an oral therapy used to lower the blood sugar level in adults with T2D and cardiovascular diseases and is contraindicated in patients with T1D and diabetic ketoacidosis

Click here ­to­ read full press release/ article | Ref: Lilly | Image: Yahoo Finance